| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
9,020 |
8,633 |
$515K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
4,627 |
4,389 |
$434K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
4,660 |
4,635 |
$204K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
1,941 |
1,940 |
$158K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
1,709 |
1,709 |
$141K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
1,113 |
1,113 |
$98K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
1,189 |
1,177 |
$92K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,629 |
1,601 |
$83K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
878 |
865 |
$72K |
| 90461 |
|
1,565 |
1,557 |
$60K |
| S0302 |
Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) |
6,181 |
6,164 |
$56K |
| 92558 |
|
1,781 |
1,780 |
$44K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
3,280 |
3,274 |
$34K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
999 |
981 |
$31K |
| 96127 |
|
2,736 |
2,733 |
$28K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,660 |
1,633 |
$22K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
919 |
906 |
$22K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,584 |
829 |
$21K |
| 99173 |
|
870 |
870 |
$15K |
| 99177 |
|
1,049 |
1,049 |
$14K |
| 83655 |
|
876 |
875 |
$10K |
| 87081 |
|
1,256 |
1,237 |
$10K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
1,147 |
1,141 |
$9K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
442 |
439 |
$7K |
| 94760 |
|
3,036 |
2,896 |
$7K |
| 36416 |
|
563 |
562 |
$5K |
| 87634 |
|
44 |
44 |
$3K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
44 |
44 |
$1K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
44 |
44 |
$1K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
13 |
13 |
$1K |
| 99188 |
|
36 |
36 |
$936.00 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
54 |
54 |
$839.30 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
15 |
15 |
$515.25 |
| 81003 |
|
198 |
195 |
$385.55 |
| 87807 |
|
16 |
16 |
$175.91 |
| 92551 |
|
12 |
12 |
$119.16 |
| 96161 |
|
12 |
12 |
$46.32 |
| J7611 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg |
44 |
43 |
$13.20 |